Company intelligence / Profile preview

SecondWave Systems

Minneapolis/St. Paul area, Minnesota, United States

Ownership: Private
Development stage: Phase 1

Overview

SecondWave Systems has demonstrated significant reduction in disease activity in a pilot clinical study of its wearable splenic ultrasound device for rheumatoid arthritis. In the 13-patient trial, 10 experienced benefit with no serious adverse events. The company is preparing for further studies and broader applications in inflammatory diseases.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: DeviceNoninvasive neuromodulation therapyUltrasound-based therapy (Low-intensity focused ultrasound)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SecondWave MINI

Phase 1

Indications: Rheumatoid arthritis, Inflammatory disorders

Partnerships

University of Minnesota Medical School (clinical trials)DARPA, ARPA-H, Department of Defense funding partners

Beyond the preview

Go deeper on SecondWave Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SecondWave Systems.

Explore the full profile